Factor VIII products and inhibitor development in severe hemophilia A.

Autores de IIS La Fe

• Ana Rosa Cid Haro

  Autor

Participantes ajenos a IIS La Fe

• Gouw SC
• van der Bom JG
• Ljung R
• Escuriola C
• Claeyssens-Donadel S
• van Geet C
• Kenet G
• Mäkipernaa A
• Molinari AC
• Muntean W
• Kobelt R
• Rivard G
• Santagostino E
• Thomas A
• van den Berg HM
• PedNet and RODIN Study Group

Grupos

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

Abstract

For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development).